Nicox Receives Complete Response Letter from the FDA Related to GMP on NDA for AC-170

Sophia Antipolis, France, 10 October 2016 -- Nicox S.A. (Euronext Paris: FR0013018124, COX), the international ophthalmic R&D company, today announced that it has received a Complete Response Letter (CRL) from the U.S. Food and Drug...
Source: Drugs.com - New Drug Applications - Category: Drugs & Pharmacology Source Type: news